PMV Pharmaceuticals Plans Workforce Reduction Of Approximately 30%; Reveals Prioritization Of PC14586 Development And Focused Discovery Research Efforts Results
Benzinga Newsdesk 2 years ago
News
Unaudited cash, cash equivalents, and marketable securities totaling approximately $229 million as of December 31, 2023, combined with cost savings from workforce reduction, is expected to extend cash runway to
Unaudited cash, cash equivalents, and marketable securities totaling approximately $229 million as of December 31, 2023, combined with cost savings from workforce reduction, is expected to extend cash runway to end of 2026